ITI-9001 enters Phase 1 as Immunomic Therapeutics tests disease-modifying allergy vaccine
See how ITI-9001 could reshape Japanese cedar allergy treatment and what its Phase 1 trial must prove on safety, efficacy and durability.
Pharma & Biotech